About Enhancer

Enhancer ID: E_01_0547
Species: human
Position : chr7:148804787-148806787
Biosample name:
Experiment class : High+Lowthroughput
Enhancer type: Enhancer
Disease: Refractory b-cell non hodgkin lymphoma, advanced solid tumor, epithelioid sarcoma
Pubmed ID:  29650362
Enhancer experiment: RNA-seq,immunohistochemistry,PCR,
Enhancer experiment description: Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.

About Target gene

Target gene : --
Strong evidence: qRT-PCR,qPCR,ChIP,3C
Less strong evidence: RNA-Seq
Target gene experiment description: Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.;Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.

About TF

TF name : EZH2(ENX-1,ENX1b,KMT6,KMT6A,WVS,WVS2,EZH2)SMARCA4(BAF190,BAF190A,BRG1,CSS4,MRD16,RTPS2,SNF2,SNF2L4,SNF2LB,SWI2,hSNF2b)
TF experiment: RNA-seq,immunohistochemistry,PCR,
TF experiment description: Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.;Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.

About Function

Enhancer function : Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.
Enhancer function experiment: Immunohistochemical staining
Enhancer function
experiment description:		 Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.

About SNP

SNP ID: --

Upstream Pathway Annotation of TF

GeneName Pathway Name Source Gene Number
EZH2 Activation of anterior HOX genes in hindbrain development during early embryogenesis reactome 120
EZH2 Oxidative Stress Induced Senescence reactome 120
EZH2 PKMTs methylate histone lysines reactome 64
EZH2 PRC2 methylates histones and DNA reactome 71
EZH2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
EZH2 Hs_Interactome_of_polycomb_repressive_complex_2_(PRC2)_WP2916_88672 wikipathways 15
SMARCA4 BMP signaling in Drosophila ( BMP signaling in Drosophila ) inoh 7
SMARCA4 BMP signaling in Drosophila (dorsal midline) ( BMP signaling in Drosophila ) inoh 7
SMARCA4 BMP signaling in Drosophila (dorsolateral) ( BMP signaling in Drosophila ) inoh 7
SMARCA4 BMP signaling pathway ( TGF-beta_BMP Diagram(MolecularVariation) ) inoh 34
SMARCA4 Direct p53 effectors pid 141
SMARCA4 Formation of the beta-catenin:TCF transactivating complex reactome 88
SMARCA4 Glucocorticoid receptor regulatory network pid 85
SMARCA4 RANKL netpath 84
SMARCA4 Regulation of nuclear beta catenin signaling and target gene transcription pid 80
SMARCA4 Regulation of retinoblastoma protein pid 67
SMARCA4 RMTs methylate histone arginines reactome 75
SMARCA4 Signaling with Wnt (Canonical) ( C. elegans endoderm induction Wnt signaling pathway Diagram ) inoh 47
SMARCA4 Signaling with Wnt (Canonical) ( Canonical Wnt signaling pathway Diagram ) inoh 47
SMARCA4 Signaling with Wnt (Canonical) ( Drosophila Wingless/Wnt signaling pathway Diagram ) inoh 47
SMARCA4 Signaling with Wnt (Canonical) ( Mammalian Wnt signaling pathway Diagram ) inoh 47
SMARCA4 Signaling with Wnt (Canonical) ( Xenopus axis formation Wnt signaling pathway Diagram ) inoh 47
SMARCA4 Signaling with Wnt (Mammal) ( Mammalian Wnt signaling pathway Diagram ) inoh 47
SMARCA4 TGF-beta_super_family_signaling_pathway(canonical) ( TGF-beta_BMP Diagram(MolecularVariation) ) inoh 51
SMARCA4 TNFalpha netpath 274
SMARCA4 Validated nuclear estrogen receptor beta network pid 15
SMARCA4 Wnt signaling pathway panther 250
SMARCA4 Hs_Integrated_Breast_Cancer_Pathway_WP1984_82941 wikipathways 122

Enhancer associated network

The number on yellow line represents the distance between enhancer and target gene

Expression of target genes for the enhancer

Enhancer associated SNPs